Norwich Pharmaceuticals v. Salix: Supreme Court Denies Cert on Xifaxan® Patents
Norwich Pharmaceuticals sought Supreme Court review of Salix Pharmaceuticals’ rifaximin (Xifaxan®) patent portfolio, asserting infringement claims across three patents covering 500 mg and 550 mg tablets. The Court denied certiorari in just 68 days, leaving Salix’s patent protections intact and Norwich’s generic entry challenge unresolved at the highest level.
Supreme Court shuts the door on Norwich’s Xifaxan® challenge
Filed on September 11, 2024, Case No. 24-294 represents Norwich Pharmaceuticals’ attempt to bring its challenge to Salix Pharmaceuticals’ rifaximin patent portfolio before the United States Supreme Court. The dispute centres on three patents — US7612199B2, US8309569B2, and US10765667B2 — which cover rifaximin (Xifaxan®) formulations in 500 mg and 550 mg tablet strengths, a blockbuster antibiotic/GI therapeutic with significant commercial value in the irritable bowel syndrome and hepatic encephalopathy markets.
The Supreme Court denied Norwich’s petition on November 18, 2024 — just 68 days after filing. A denial of certiorari is not a ruling on the merits; it signals only that fewer than four Justices voted to grant review. The practical effect, however, is decisive: the lower court judgment defending Salix’s patent rights remains in full force, and Norwich’s pathway to launching a generic or competing rifaximin product through this legal route is exhausted at the federal appellate peak.
The speed of the denial — roughly half the typical cert petition timeline — suggests the Court found no compelling circuit split, novel constitutional question, or pressing federal interest warranting review. What remains undisclosed from the public record is the precise lower court ruling Norwich sought to challenge, the specific legal theory advanced in the petition, and whether any settlement or licensing discussions accompanied or followed the denial. Norwich’s commercial options now likely depend on alternative ANDA or IPR strategies.
Filing to Petition Dismissed in 68 days
68-day petition cycle — Supreme Court cert petitions typically resolve in 90–120 days; this denial came notably faster
Certiorari denied: what the Supreme Court’s refusal means for both parties
Denial of certiorari is not a merits ruling
When the Supreme Court denies a petition for certiorari, it does not affirm the lower court’s reasoning or endorse its legal analysis. The denial simply means the Court declined to exercise its discretionary jurisdiction. Fewer than 1% of cert petitions are granted. The operative legal effect is that the lower tribunal’s judgment — here, preserving Salix’s patent rights — stands as the final word in this litigation.
Procedural dismissalSalix’s rifaximin patents survive Norwich’s highest-level challenge
With certiorari denied, Salix Pharmaceuticals retains the enforceability of US7612199B2, US8309569B2, and US10765667B2 against Norwich without any Supreme Court-level erosion. The denial effectively ends this litigation thread. Salix can now enforce its Xifaxan® patent position with the added procedural weight of an exhausted appellate path, strengthening its negotiating posture in any future licensing or ANDA dispute with Norwich or other generic challengers.
Patent position preservedNorwich’s Supreme Court route is closed — alternatives remain
Norwich has exhausted the direct judicial review pathway through the federal courts for this litigation. The cert denial does not legally preclude Norwich from pursuing inter partes review (IPR) petitions at the USPTO, filing a new ANDA supported by revised non-infringement or invalidity arguments, or seeking to design around the asserted claims. However, the denied petition may complicate future invalidity arguments by signalling that no federal court found the underlying legal questions sufficiently novel or contested to warrant review.
Appellate route exhaustedXifaxan® exclusivity intact — generic entry delayed further
Rifaximin is a high-value GI therapeutic generating billions in annual revenue for Salix. The cert denial reinforces the durability of the three-patent Xifaxan® portfolio against at least Norwich’s challenge, likely deterring near-term generic market entry via this litigation pathway. Other ANDA filers and biosimilar strategists in the GI antibiotic space should treat this outcome as a signal that the Salix patent cluster has now withstood challenge through the highest available federal forum.
Brand exclusivity reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Norwich Pharmaceuticals | Individual | Generic pharmaceutical company — petitioner challenging holder of US7612199B2, US8309569B2, US10765667B2Search in Eureka ↗ |
| Defendant | Salix Pharmaceuticals, Ltd., et al. | Company | Branded pharmaceutical company; holds rifaximin (Xifaxan®) patent portfolio; respondent in Supreme Court petitionSearch in Eureka ↗ |
| Plaintiff counsel | Ian Swan | Attorney | Counsel for Norwich PharmaceuticalsSearch in Eureka ↗ |
| Plaintiff counsel | Matthew J. Becker | Attorney | Counsel for Norwich PharmaceuticalsSearch in Eureka ↗ |
| Plaintiff counsel | Matthew S. Murphy | Attorney | Counsel for Norwich PharmaceuticalsSearch in Eureka ↗ |
| Plaintiff counsel | Thomas Knut Hedemann | Attorney | Counsel for Norwich PharmaceuticalsSearch in Eureka ↗ |
| Plaintiff law firm | Axinn Veltrop & Harkrider, LLP | Law Firm | Representing Norwich PharmaceuticalsSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The terse ‘Petition DENIED’ disposition is standard Supreme Court practice and carries no explanatory opinion. It does not constitute a ruling on the merits of Norwich’s infringement or invalidity arguments, nor does it signal judicial approval of the lower court’s legal reasoning. Under established doctrine (see Maryland v. Baltimore Radio Show, 338 U.S. 912), a denial of certiorari has no precedential value. For Salix, the practical consequence is dispositive: the lower judgment stands unchallenged at the federal level, and the three rifaximin patents retain full enforceability against Norwich’s challenged conduct.
US7612199B2, US8309569B2 & US10765667B2 — Rifaximin (Xifaxan®) tablet formulations
The three asserted patents — US7612199B2 (App. No. 12/478638), US8309569B2 (App. No. 12/393979), and US10765667B2 (App. No. 16/738392) — collectively cover rifaximin, a minimally absorbed oral antibiotic used to treat irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy. The application filing dates span multiple years, suggesting a deliberate staggered prosecution strategy designed to extend effective market exclusivity across different claim types, including formulation, composition, and potentially method-of-use claims covering the 500 mg and 550 mg tablet strengths marketed as Xifaxan®.
Rifaximin is among the most commercially significant GI drugs in the U.S. market, generating multi-billion dollar revenues for Salix (a subsidiary of Bausch Health). The three-patent cluster creates a thicket that generic challengers must dismantle entirely before a non-infringing ANDA launch is viable. The staggered application numbers across two distinct application families (12/x and 16/x series) are consistent with continuation and continuation-in-part strategies that extend protection well beyond the original priority date, a pattern common in Hatch-Waxman-intensive therapeutic areas.
Should your rifaximin product trigger an FTO against US7612199B2 and related patents?
Any company developing, manufacturing, or seeking to commercialise a rifaximin-based oral tablet — particularly in 500 mg or 550 mg strengths — in the U.S. market should treat this patent cluster as a priority FTO target. The Supreme Court denial confirms that at least one challenger failed to dislodge these patents through the full federal litigation ladder. Generic ANDA filers, specialty pharma licensees, and contract manufacturers should assess each of the three patents independently for claim scope, expiry dates, and potential design-around opportunities before committing to development spend.
PatSnap Eureka’s FTO Search Agent enables rapid landscape mapping across the Salix rifaximin portfolio, including claim-level analysis of US7612199B2, US8309569B2, and US10765667B2, prosecution history flags, and identification of related family members that may extend geographic or claim coverage. R&D teams can use Eureka to benchmark proposed formulations against asserted claim limitations and to surface any post-grant proceedings — IPRs, PGRs — that may have narrowed or maintained the patents’ enforceable scope.
Run a freedom-to-operate analysis on US7612199B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman and rifaximin patent cases in U.S. federal courts
Cases involving Hatch-Waxman ANDA challenges to GI pharmaceutical patents, including rifaximin and specialty antibiotic formulation disputes in U.S. district and appellate courts.
What this case signals for the rifaximin and GI pharmaceutical IP landscape
Three Xifaxan® patents survived to the Supreme Court level. The denial reshapes generic entry strategy across the GI antibiotic space.
Cert denial raises the bar for future rifaximin generic challengers
Any generic or ANDA filer seeking to challenge the Xifaxan® patent cluster now faces a portfolio that has survived district court, appellate, and Supreme Court scrutiny in this thread. New challengers must identify distinct invalidity theories or design-around approaches not previously adjudicated. IPR at the USPTO remains the most viable route, but even there, the commercial and litigation history will inform PTAB’s assessment of petition merit.
Three-patent portfolio strategy: a model for branded GI drug protection
Salix’s layered protection across formulation, composition, and method-of-use patents (US7612199B2, US8309569B2, US10765667B2) illustrates how staggered patent filings across multiple application families can create overlapping exclusivity that generic challengers must defeat in its entirety. R&D and IP teams in the specialty pharma space should benchmark this cluster strategy when building defensive portfolios around blockbuster therapeutics.
Pharmaceuticals v Salix — key questions answered
A denial of certiorari means the Supreme Court declined to review the lower court’s decision. It is not a ruling on the merits of Norwich’s infringement or invalidity arguments. The practical effect is that the lower tribunal’s judgment — preserving Salix’s patent rights over the three rifaximin patents — stands as the final judicial outcome in this litigation thread.
Three patents were asserted: US7612199B2 (App. No. 12/478638), US8309569B2 (App. No. 12/393979), and US10765667B2 (App. No. 16/738392). All three relate to rifaximin formulations marketed as Xifaxan® in 500 mg and 550 mg tablet strengths by Salix Pharmaceuticals.
Yes. A certiorari denial does not create estoppel blocking all future challenges. Norwich may still petition the USPTO for inter partes review (IPR) of the three patents, provided time bars under 35 U.S.C. § 315(b) have not elapsed. Norwich could also file a new ANDA supported by revised non-infringement contentions or design-around formulations not captured by the asserted claims.
The petition was filed on September 11, 2024, and denied on November 18, 2024 — a duration of 68 days. This is notably faster than the typical Supreme Court cert petition resolution window of 90–120 days, suggesting the Court found no compelling basis for review relatively quickly.
Rifaximin (Xifaxan®) is a high-revenue GI antibiotic used for IBS-D and hepatic encephalopathy, generating multi-billion dollar annual revenues for Salix (a Bausch Health subsidiary). The three asserted patents form an overlapping portfolio that, following the cert denial, has now withstood challenge at every level of the U.S. federal court system in this case, reinforcing Salix’s exclusivity position against generic entry via Norwich’s litigation pathway.
PatSnap Eureka searches patents and litigation data to answer instantly.